# Swift Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/swift-biosciences

- Industry: Pharmaceuticals
- Headquarters: Ann Arbor, US
- Website: www.swiftbiosci.com
- Total disclosed funding: $26M
- Latest round: Series D (Jun 29, 2017)
- Investors on record: 7

## About

Swift Biosciences Inc. specializes in innovative biotechnology solutions that enhance diagnostic capabilities and support life sciences research through advanced genetic sequencing technologies.Founded in 2010 and headquartered in Ann Arbor, US, Swift Biosciences Inc. develops products focused on genomic analysis. In March 2021, Integrated DNA Technologies, Inc. acquired the company for an undisclosed sum. The company has completed a total of 11 deals since its inception, with the latest funding round raising USD 4.00 mn.Swift Biosciences Inc. offers biotechnology solutions aimed at enhancing diagnostic capabilities and advancing life sciences research. Their flagship products incorporate advanced genetic sequencing technologies, facilitating accurate genomic analysis and applications in personalized medicine. These solutions are designed to streamline workflows in clinical laboratories and research institutions, addressing critical needs in disease detection and management. Utilized by healthcare providers, pharmaceutical companies, and academic institutions, their products cover various end-use cases, including cancer research, genetic disorder screening, and infectious disease diagnostics. The company distributes its offerings in North America, Europe, and select Asian markets, maintaining a global client base reliant on their technology to drive advancements in healthcare.The revenue model of Swift Biosciences Inc. is primarily based on direct sales and partnerships with key stakeholders in the healthcare and research sectors. Transactions typically occur through B2B arrangements, where clients procure advanced diagnostic products on a subscription basis or through one-time purchases. The pricing structure is tiered, accommodating different client needs and scales, ensuring accessibility for laboratories from small clinical practices to large research facilities. The diverse client portfolio includes hospitals, research institutions, and biotechnology firms, which supports a robust revenue stream through ongoing demand for specialized products and services.Swift Biosciences Inc. plans to utilize the funding raised in March 2021 to enhance its product offerings and expand its market presence. The company is designing new products aimed at improving genetic testing capabilities, with plans for a phased launch in 2022. Furthermore, it intends to expand into emerging markets in Asia and Europe by 2023, leveraging advancements in biotechnology to reach a wider audience. Recent funding will support these initiatives, facilitating research and development efforts to meet growing demands in the biotechnology sector.

## Funding rounds

- Series D, Jun 29, 2017, $12M — Arboretum Ventures
- Series C, Apr 15, 2016, $3.3M — Fletcher Spaght Ventures, Michigan Accelerator Fund, Draper
- Series B, Oct 11, 2013, $7M — Fletcher Spaght Ventures, Mercury, Renaissance Venture Capital, Charter Capital Partners
- Series A, Jan 15, 2013, $0.8M — Charter Capital Partners
- Series A, Aug 10, 2010, $3M — Mercury

## Investors

- Mercury (https://capitalatlas.ai/funds/mercury) — Series A, Series B
- Charter Capital Partners (https://capitalatlas.ai/funds/charter-capital-partners) — Series A, Series B
- Fletcher Spaght Ventures (https://capitalatlas.ai/funds/fletcher-spaght-ventures) — Series B, Series C
- Renaissance Venture Capital (https://capitalatlas.ai/funds/renaissance-venture-capital) — Series B
- Michigan Accelerator Fund — Series C
- Draper (https://capitalatlas.ai/funds/draper) — Series C
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series D